17 September 2026

CoinShares XBT Provider AB (Publ)

Issuance Programme for the issue of Bitcoin Tracker Certificates and Ethereum Tracker Certificates

LEI: 549300HGWKR2Q5T8GK64

Publication of Base Prospectus


Stockholm, 17 September 2026 – CoinShares XBT Provider AB (Publ) (the “Company”) announces the publication of its updated prospectus, approved by the Swedish Financial Supervisory Authority and published on 17 September 2026. The full document will be made available on the Company’s website.  

Interested persons may access an electronic copy of these documents at:

https://coinshares.com/etp/documents/

For further information, please contact:

CoinShares XBT Provider AB (Publ)
Artillerigatan 6,
114 51 Stockholm
Sweden

ir@xbtprovider.com

Approval follows successful multi-state validation across several locations, building on initial commercial rollout earlier this year and enabling adoption across the chain’s U.S. franchise system.

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, today announced an important milestone in its previously disclosed commercial relationship with a renowned American fast-food chain.

Following the initial commercial rollout that commenced earlier this year, the restaurant chain has now approved Beyond Oil for system-wide use across its hundreds of franchise partner locations throughout the United States.

The approval follows successful validation across several restaurant locations in three states, building on the initial rollout with three franchisees earlier this year. The expanded evaluation focused on food quality, oil quality, worker safety and the ease of integrating Beyond Oil into existing restaurant operations.

With the formal evaluation process completed, the restaurant chain plans to support broader adoption across its U.S. franchise system through its internal best practices, standard operating guidelines and operations training teams. As part of the ongoing relationship, Beyond Oil will also be invited to participate in the brand’s franchise events and conferences, providing direct engagement with franchise partners across the system.

“These relationships take time to build. You need to earn credibility with the customer, build trust and prove that the product works consistently in their real operating environment,” said Jonathan Or, CEO of Beyond Oil. “We have tremendous respect for the way this brand puts food quality at the center of its decision-making and for the care it takes before introducing something new across its system. Reaching system-wide approval is therefore a meaningful milestone for us. It opens the door to broader adoption across the organization and creates the opportunity for Beyond Oil to become part of a new operating standard. We have spent the past year building similar relationships and progressing through these processes with several other restaurant chains, including groups of comparable and larger scale, and we look forward to advancing these relationships toward potential approvals and commercial milestones in the months ahead.”

About Beyond Oil Ltd.
We all love fried food. Let’s make it better. Not by changing what people love. By improving the system behind it. Beyond Oil Ltd. (TSX: BOIL, OTCQB: BEOLF) is a food-tech innovation company on a mission to help foodservice operators improve fried food across every dimension that matters: quality, health, consistency, safety, sustainability and profitability. We achieve these outcomes by improving the system behind every kitchen, the frying performance and oil management that determine what lands on the plate. The Company’s patented technology, cleared by the FDA and Health Canada, integrates into existing kitchen workflows to improve frying performance and oil management, helping operators deliver more consistent food, strengthen operational control and reduce oil waste. Beyond Oil’s solution serves restaurant chains, supermarkets, hotels, catering, institutions and industrial frying operations worldwide, turning frying into a measurable, repeatable and scalable brand standard. The result is a better frying standard, helping every fryer, every shift and every plate live up to the food people love. For more information, please visit: www.beyondoil.co.

Forward-Looking Statements and Information
This news release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect Beyond Oil Ltd.’s current views with respect to, among other things, its operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Beyond Oil Ltd. are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions.  Although Beyond Oil Ltd., believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the USA and Canada, certain factors, not presently known to Beyond Oil Ltd., or that Beyond Oil Ltd., currently believes are not material, could cause actual results to differ materially from those contemplated or implied by forward-looking statements.  Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to us as of the date of this news release. Except as required by law, Beyond Oil Ltd., undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.  In particular, this news release contains forward-looking statements regarding: the adoption of Beyond Oil across the restaurant chain’s franchise system; the brand’s plans to support adoption through best practices, training, and franchise events; the potential for Beyond Oil to become part of a new operating standard; and management’s expectations regarding progress, pipeline development, and potential future approvals with other restaurant chains. Forward-looking statements are subject to specific risks and uncertainties, including that system-wide approval authorizes but does not guarantee adoption or minimum order volumes by individual franchise partners; the timing, pace, and extent of franchisee onboarding across locations; customer retention and re-order rates; operational and supply-chain logistics; and that ongoing discussions and evaluations with other restaurant chains may not lead to commercial agreements or system-wide approvals.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Adi Olesker, VP of Investor Relations
Phone: +972-50-694-2517
adio@beyondoil.co

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
BOIL@arxhq.com

DALLAS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Westwood Holdings Group (NYSE: WHG), a leading boutique asset manager, today announced the launch of the Westwood Salient Enhanced Power & Infrastructure ETF (TXSE: PWRX), the newest addition to the Westwood Enhanced Income Series™ ETFs. PWRX is the first new ETF to launch on the Texas Stock Exchange (TXSE), marking the opening of a new national listings venue and the start of the next chapter of American capital markets being written in Texas.

PWRX expands the Westwood Enhanced Income Series™ by pairing an income strategy with exposure to the high-growth elements of the energy market. After nearly two decades of flat electricity demand, the United States is entering a new era of accelerating power needs driven by AI, data centers and industrial reshoring. PWRX (“Power-X”) is an actively managed ETF designed to help investors benefit from this modern power renaissance. The portfolio invests across the power ecosystem, from traditional energy and utilities to grid infrastructure, data-center infrastructure and next-generation energy technologies. The strategy, managed by Westwood’s veteran Houston-based Energy Team, combines a high-conviction equity portfolio with a systematic covered call overlay. PWRX seeks to generate attractive monthly income while participating in one of the market’s most compelling long-term growth opportunities.

“Listing the first new ETF on the Texas Stock Exchange is a milestone we are proud to share with our home state,” said Brian Casey, Chief Executive Officer of Westwood Holdings Group. “Westwood has called Texas home for over three decades. As a Dallas-based asset manager with a Houston-based energy team, launching PWRX on a Texas-based exchange reflects our commitment to innovation and leadership right where we live and work. This is what we believe the next chapter of American capital markets looks like, and it is being written in Texas.”

“PWRX debuting on our exchange is more than a defining moment for TXSE, it is capital markets history being made right here in Texas,” said James H Lee, Chief Executive Officer of the Texas Stock Exchange. “We believe Texas doesn’t wait for the future — it builds it. There is no more fitting way to launch our first new ETF than with a Texas asset manager giving investors exposure to the industries powering what comes next.”

Key features of PWRX include:

  • An actively managed portfolio of power, energy and infrastructure companies positioned for accelerating electricity demand
  • A single-stock covered call options overlay designed to help generate income and help mitigate volatility
  • Potential for monthly income distributions
  • Potential for capital appreciation across the energy and power sector

“The economy is being reshaped by an unprecedented surge in power demand, and the companies that generate, move and modernize that power sit at the center of it,” said Parag Sanghani, CFA, Senior Portfolio Manager of PWRX at Westwood. “PWRX gives investors active exposure to that theme, paired with an options overlay engineered to help turn it into a steady stream of monthly income. Our Houston-based team has spent decades in these markets, and PWRX reflects that hands-on, fundamentally driven approach.”

PWRX joins the Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST), Westwood Salient Enhanced Energy Income ETF (NASDAQ: WEEI) and Westwood Enhanced Income Opportunity ETF (NYSE: YLDW) in the Westwood Enhanced Income Series™ ETFs, reinforcing Westwood’s position as an innovative provider of income ETFs across multiple sectors and asset classes.

For more information on the Westwood Salient Enhanced Power & Infrastructure ETF (PWRX) and other Westwood strategies, please visit westwoodetfs.com.

ABOUT WESTWOOD HOLDINGS GROUP, INC.

Westwood Holdings Group (NYSE: WHG) is a boutique asset management firm that offers a diverse array of actively and passively-managed, outcome-oriented investment strategies, along with white-glove trust and wealth services, to

institutional, intermediary and private wealth clients. For over 40 years, Westwood’s client-first approach has fostered strong, long-term client relationships due to our unwavering commitment to delivering bespoke investment strategies with a vehicle-optimized approach, exceptional counsel and unparalleled client service. Our flexible and agile approach to investing allows us to adapt to constantly changing markets, while continually seeking innovative strategies that meet our investors’ short and long-term needs.

Our team at Westwood comes from varied backgrounds and life experiences, which reflects our origins as a woman-founded firm. We are committed to incorporating diverse insights and knowledge into all aspects of our services and solutions. Our culture and approach to our business reflect our core values—integrity, reliability, responsiveness, adaptability, teamwork and driving results—and underpin our constant pursuit of excellence.

For more information on Westwood, please visit westwoodgroup.com.

ABOUT THE TEXAS STOCK EXCHANGE

Texas Stock Exchange LLC, a wholly owned subsidiary of TXSE Group, is a fully integrated, electronic, national securities exchange headquartered and incorporated in Texas. Backed by many of the largest financial institutions and liquidity providers in the world, TXSE is purpose-built to bring real competition to corporate listings and expand access to America’s public markets. With issuer alignment and transparency at its core, TXSE serves as a global listing and trading venue for both public companies and the growing universe of exchange-traded products.

Media Contact:

Tyler Bradford
Hewes Communications 212.207.9454
tyler@hewescomm.com

To determine if this Fund is an appropriate investment for you, carefully consider the Fund’s investment objectives, risk factors and charges and expenses before investing. This and other information can be found in the Fund’s prospectus which may be obtained by downloading at westwoodetfs.com or calling 800.994.0755.
Please read the prospectus carefully before investing.

Westwood ETFs are distributed by Northern Lights Distributors, LLC (Member FINRA). Northern Lights Distributors and Westwood ETFs (or Westwood Holdings Group, Inc.) are separate and unaffiliated.

The Fund is newly formed and has limited operating history.

Important Risks

Exchange Traded Funds (ETFs) are subject to market risk, including the possible loss of principal. There is no guarantee that any investment strategy will achieve its objectives, generate profits or avoid losses. The value of the portfolio will fluctuate with the value of the underlying securities. ETFs trade like a stock, and there will be brokerage commissions associated with buying and selling exchange traded funds unless trading occurs in a fee-based account. ETFs may trade for less than their net asset value. Investing in ETFs may not be suitable for all investors. ETFs are subject to loss of principal and there is no guarantee the holdings will continue to pay dividends. Diversification does not ensure a profit and may not protect against loss in declining markets. Investors should refer to the individual ETF prospectus for a more detailed discussion of the specific risks and considerations for an individual ETF.

Covered Call Strategy Risk: This risk arises when an investor holds a long position in a stock and simultaneously sells a call option against it. While this strategy can generate income, it limits potential upside gains if the stock price rises significantly above the strike price of the option.

Counterparty Risk: This is the risk that a counterparty to a financial transaction will default on their obligations. In the context of options trading, counterparty risk arises from the possibility that the option seller (writer) may not be able to fulfill their obligation to deliver the underlying asset if the option expires in-the-money.

Options Risk/Flex Options Risk: This refers to the inherent risks associated with trading options, such as the risk of losing the entire premium paid for an option if it expires out-of-the-money. Flex options risk is a specific type of options risk that arises from the flexibility of flex options, which can be adjusted or exercised under certain conditions.

Portfolio Turnover Risk: This is the risk associated with frequent buying and selling of assets within a portfolio. High portfolio turnover can lead to increased transaction
costs, potential capital gains taxes, and the possibility of missing out on potential gains from assets that are sold too early.

MLPs Risk: Investments in the debt and equity securities of MLPs involve risks that differ from investments in the debt an d equity securities of corporate issuers, including risks related to limited control and limited rights to vote on matters affecting the partnership, risks related to potential conflicts of interest between the partnership and its general partner, cash flow risks, dilution risks and risks related to the general partner’s right to require unitholders to sell their common units at an undesirable time or price. The Fund and its shareholders are not eligible for a tax deduction based on income received from MLPs that is available to individuals who invest directly in MLPs.

Concentration Risk: The Fund concentrates its investments in issuers of one or more particular industries to the extent permitted by applicable regulatory guidance. There is a risk that those issuers (or industry sector) will perform poorly and negatively impact the Fund. Concentration risk results from maintaining exposure (long or short) to issuers conducting business in a specific industry. The risk of concentrating investments in a limited number of issuers in a particular industry is that the Fund will be more susceptible to market, economic, political, regulatory, and other conditions and risks associated with that industry than a fund that does not concentrate its investments and invests more broadly across industries and sectors.

Westwood ETFs does not provide tax advice. Please consult your tax advisor before making any decisions or taking any action based on this information.

Industry Specific Risk: The Power and Infrastructure Companies in which the Fund invests, are subject to risks specific to the industry they serve, including the following:

Energy Sector Risk: The Fund will be sensitive to changes in, and its performance will depend to a greater extent on, the overall condition of the energy sector. Companies operating in the energy sector are subject to risks including, but not limited to, economic growth, worldwide demand, political instability in the regions that the companies operate, government regulation stipulating rates charged by utilities, interest rate sensitivity, oil price volatility, energy conservation, environmental policies, depletion of resources, and the cost of providing the specific utility services and other factors that they cannot control. The energy sector is cyclical and is highly dependent on commodity prices; prices and supplies of energy may fluctuate significantly over short and long periods of time due to, among other things, national and international political changes, OPEC policies, changes in relationships among OPEC members and between OPEC and oil-importing nations, the regulatory environment, taxation policies, and the economy of the key energy-consuming countries. Commodity prices have recently been subject to increased volatility and declines, which may negatively affect companies in which the Fund invests. Companies in the energy sector may be adversely affected by terrorism, natural disasters or other catastrophes. Companies in the energy sector are at risk of civil liability from accidents resulting in injury, loss of life or property, pollution or other environmental damage claims and risk of loss from terrorism and natural disasters. Disruptions in the oil industry or shifts in fuel consumption may significantly impact companies in this sector. Significant oil and gas deposits are located in emerging markets countries where corruption and security may raise significant risks, in addition to the other risks of investing in emerging markets. Companies in the energy sector may also be adversely affected by changes in exchange rates, tax treatment, government regulation and intervention, negative perception, efforts at energy conservation and world events in the regions in which the companies operate (e.g., expropriation, nationalization, confiscation of assets and property or the imposition of restrictions on foreign investments and repatriation of capital, military coups, social unrest, violence or labor unrest). Because a significant portion of revenues of companies in this sector is derived from a relatively small number of customers that are largely comprised of governmental entities and utilities, governmental budget constraints may have a significant impact on the stock prices of companies in this sector. The energy sector is

highly regulated. Entities operating in the energy sector are subject to significant regulation of nearly every aspect of their operations by federal, state and local governmental agencies. Such regulation can change rapidly or over time in both scope and intensity. Stricter laws, regulations or enforcement policies could be enacted in the future which would likely increase compliance costs and may materially adversely affect the financial performance of companies in the energy sector. A downturn in the energy sector of the economy, adverse political, legislative or regulatory developments or other events could have a larger impact on the Fund than on an investment company that does not invest a substantial portion of its assets in the energy sector. At times, the performance of securities of companies in the energy sector may lag the performance of other sectors or the broader market as a whole. The price of oil, natural gas and other fossil fuels may decline and/or experience significant volatility, which could adversely impact companies operating in the energy sector.

Electricity Related Companies Risk. Electricity related companies are subject to general risks of companies involved with generating, storing, supplying, and transmitting electricity and include regulation of those businesses, the general state of the economy, intense competition, consolidation, domestic and international politics, and excess capacity. In addition, electrical companies may also be affected by overall capital spending levels (including both private and public sector spending), economic cycles, technological obsolescence, delays in modernization, and labor relations. Companies in the various electrical industries may also be significantly impacted by government policies, regulations, import controls, and contractual fixed pricing. Actions taken by central governments may dramatically impact supply and demand forces that influence the market price of conventional and alternative electricity, resulting in sudden decreases in value.

Oil and Gas Companies Risk. The profitability of oil and gas companies is related to worldwide energy prices, including all sources of energy, and exploration and production costs. The price of oil and gas, the earnings of oil and gas companies, and the value of such companies’ securities can be extremely volatile. Such companies are also subject to risks of changes in commodity prices, changes in the global supply of and demand for oil and gas, interest rates, exchange rates, the price of oil and gas, the prices of competitive energy services, the imposition of import controls, world events, friction with certain oil-producing countries and between the governments of the United States and other major exporters of oil to the United States, actions of OPEC, negative perception and publicity, depletion of resources, development of alternative energy sources, energy conservation, technological developments, labor relations and general economic conditions, as well as market, economic and political risks of the countries where oil and gas companies are located or do business, fluctuations caused by events relating to international politics, including political instability, expropriation, social unrest and acts of war, acts of terrorism, energy conservation, the success of exploration projects and tax and other governmental regulatory policies. Oil and gas companies operate in a highly competitive and cyclical industry, with intense price competition. A significant portion of their revenues may depend on a relatively small number of customers, including governmental entities and utilities. Oil and gas companies are exposed to significant and numerous operating hazards. Oil and gas equipment and services, as well as oil and gas exploration and production, can be significantly affected by natural disasters and adverse weather conditions in the regions in which they operate.
The revenues of oil and gas companies may be negatively affected by contract termination and renegotiation. Oil and gas companies are subject to, and may be adversely affected by, extensive federal, state, local and foreign laws, rules and regulations. Oil and gas exploration and production companies may also be adversely affected by environmental damage claims and other types of litigation. Laws and regulations protecting the environment may expose oil and gas companies to liability for the conduct of or conditions caused by others or for acts that complied with all applicable laws at the time they were performed. The international operations of oil and gas companies expose them to risks associated with instability and changes in economic and political conditions, social unrest and acts of war, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international business. Such companies may also have significant capital investments or operations in, or engage in transactions involving, emerging market countries, which may increase these risks.

Midstream Energy Companies Risk. Midstream energy companies that provide crude oil, refined product and natural gas services are subject to supply and demand fluctuations in the markets they serve which may be impacted by a wide range of factors, including fluctuating commodity prices, weather, increased conservation, increased governmental or environmental regulation, depletion, rising interest rates, declines in domestic or foreign production, accidents or catastrophic events, increasing operating expenses and economic conditions.

Marine Shipping Energy Companies Risk. Marine shipping energy companies are primarily marine transporters of natural gas, crude oil or refined petroleum products. Marine shipping companies are exposed to many of the same risks as other energy companies. The highly cyclical nature of the marine transportation industry may lead

to volatile changes in charter rates and vessel values, which may adversely affect the revenues, profitability and cash flows of energy companies with marine transportation assets. Fluctuations in charter rates result from changes in the supply and demand for vessel capacity and changes in the supply and demand for certain energy commodities. Changes in demand for transportation of commodities over longer distances and supply of vessels to carry those commodities may materially affect revenues, profitability and cash flows. The value of marine transportation vessels may fluctuate and could adversely affect the value of shipping company securities in the Fund’s portfolio. Declining marine transportation values could affect the ability of shipping companies to raise cash by limiting their ability to refinance their vessels, thereby adversely impacting such company’s liquidity.
Shipping company vessels are at risk of damage or loss because of events such as mechanical failure, collision, human error, war, terrorism, piracy, cargo loss and bad weather. In addition, changing economic, regulatory and political conditions in some countries, including political and military conflicts, have from time to time resulted in attacks on vessels, mining of waterways, piracy, terrorism, labor strikes, boycotts and government requisitioning of vessels. These sorts of events could interfere with shipping lanes and result in market disruptions and a significant reduction in cash flow for the shipping companies.

Geopolitical Risk. Global political and economic instability could affect the operations of energy companies in unpredictable ways, including through disruptions of natural resource supplies and markets and the resulting volatility in commodity prices. Market disruptions arising out of geopolitical events could also prevent the Fund from executing advantageous investment decisions in a timely manner.

Nuclear Industry Risk. Companies in the Nuclear Industry may face considerable risk as a result of, among other risks, incidents and accidents, breaches of security, ill-intentioned acts of terrorism, air crashes, natural disasters (such as floods or earthquakes), equipment malfunctions or mishandling in storage, handling, transportation, treatment or conditioning of substances and nuclear materials. Such events could have serious consequences, especially in case of radioactive contamination and irradiation of the environment, for the general population, as well as a material, negative impact on the Fund’s portfolio companies. In addition, nuclear energy and technology companies are subject to competitive risk associated with the prices of other energy sources, such as natural gas and oil. Consumers of nuclear energy may have the ability to switch between nuclear energy and other energy sources and, as a result, during periods when competing energy sources are less expensive or nuclear energy sources are out of favor, the revenues of nuclear energy companies may decline with a corresponding impact on earnings.

Utilities Sector Risk. Companies in the utilities sector may be adversely affected by changes in exchange rates, domestic and international competition and governmental regulations on rates charged to customers.
Privatization and deregulation in the utilities sector may subject companies to greater competition and losses in profitability. Companies in the utilities sector may have difficulty obtaining an adequate return on invested capital, raising capital, or financing large construction programs during periods of inflation or unsettled capital markets. In addition, companies in the utilities sector may be adversely affected due to increase in fuel and operating costs and the costs of complying with regulations. Furthermore, natural disasters, terrorist attacks, government intervention or other factors may render a utility company’s equipment unusable or obsolete and negatively impact profitability.

Industrial Companies Risk. Industrial companies face a number of risks, including supply chain and distribution disruptions, business interruptions, product obsolescence, third-party vendor risks, cyber attacks, trade disputes, product recalls, liability claims, scarcity of materials or parts, excess capacity, changes in consumer preferences, and volatility in commodity prices and currencies. The performance of such companies may also be affected by technological developments, labor relations, legislative and regulatory changes, government spending policies, and changes in domestic and international economies.

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company“) (CSE: BRU), is pleased to announce that it has engaged Palliser Exploration Ltd. (“Palliser”) to carry out a comprehensive geochemical soil sampling survey for the CW Copper Project (“CW”, or the “Project”), located approximately one hundred (100) kilometres north of Kamloops, British Columbia. Brutus has an option to earn a 100% interest in five (5) contiguous mineral claims at CW totaling 2,894.56 hectares that cover historical, early-stage stratiform massive sulphide occurrences.

Highlights of the CW Copper Project

  • Located within Paleozoic metasedimentary and metavolcanic rocks of the Eagle Bay Assemblage and Fennell Formation — a mineral belt prospective for both volcanogenic massive sulphides (“VMS”) and structurally controlled gold-bearing vein deposits.
  • Host to five (5) historical copper-gold ± silver-lead-zinc mineral showings: McCarthy (semi-massive sulphide), Honeymoon and the past-producing Queen Bess (polymetallic veins), and Axel 1 and 2 (disseminated to massive sulphides).1
  • Excellent year-round access via Highway 5 and existing forest service roads. Kamloops, BC is a regional well-established mining hub that offers a wide variety of exploration services and experienced contractors.

CW Copper Project Location Map(2)
Figure 1 – CW Copper Project Location Map2

About the CW Soil Survey

The 2026 soil survey is planned to consist of approximately fifteen hundred (1,500) soil samples collected on 100 metre spaced lines at 100 metre intervals along each line (the “Survey”), which is designed to provide Project-wide exploration scope to infill areas of the Project not covered by the limited soil sampling conducted by historical exploration (Please see Figure 2). The objective of the Survey is to detect additional areas at CW that may be anomalous for copper, gold, silver, lead and zinc in order to provide a baseline for future exploration by the Company. Work is expected to commence on or about September 21, 2026 and be completed by mid-October 2026.

CW Copper Project Showings and Soil Survey Sample Locations
Figure 2 – CW Copper Project Showings and Soil Survey Sample Locations

References:

1 – NI-43-101 Technical Report on the CW Property, British Columbia, effective January 6, 2026, by Strickland, D., P.Geo.

2 – NI-43-101 Technical Report on the Chu Chua Property, British Columbia, effective September 1, 2021, by Raffel, J., et al.

Statement of Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Luke van der Meer, P. Geo., a geological consultant to the Company and a Qualified Person for Brutus as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. van der Meer has examined information regarding the historical and current exploration at CW, which includes a high-level review of the historical sampling, analytical, and procedures underlying the information and opinions contained herein.

The qualified person has not verified the information on the adjacent properties. Mineralization hosted on adjacent and/or nearby and/or geologically similar properties is not necessarily indicative of mineralization hosted on the Company’s CW Property.

Management cautions that historical results collected and reported by operators unrelated to Brutus have not been verified nor confirmed by its Qualified Person; however, the historical results create a scientific basis for ongoing work at CW. Management further cautions that references to historical results, discoveries and published resource estimates on adjacent or nearby mineral properties, or other properties located within the Eagle Bay Assemblage and Fennell Formation, whether in reference to stated current resource estimates or historical resource estimates, are not necessarily indicative of the results that may be achieved on the Project.

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU) is a mineral exploration company focused on the acquisition, exploration, and advancement of high potential copper-gold assets in Tier-1 mining jurisdictions. The Company’s flagship asset is the CW Property, a 2,894-hectare copper-gold project located approximately 100 kilometres north of Kamloops, British Columbia, as described herein. Brutus is committed to unlocking value for its shareholders through systematic exploration of district-scale projects positioned to benefit from the growing global demand for critical minerals. The Company continues to assess other critical minerals properties in Canada in order to build a well-structured property portfolio, thus offering multiple opportunities to investors for new mineral discoveries.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
+1 (604) 636-7335
info@brutusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Brutus, future growth potential for Brutus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Brutus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; potential benefits of conducting the Survey. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d0f54b47-dfd2-44d6-ac09-72f6fe8d9209

https://www.globenewswire.com/NewsRoom/AttachmentNg/8a8d3649-9deb-42d6-9e31-f24d093bae96

Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care from a healthcare professional in the U.S. last year.

It is the leading cause of iron deficiency and anemia among premenopausal women, and the primary symptom driving hysterectomies in the U.S.

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 17, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual bleeding.

HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. In preclinical studies, HMB-003 demonstrated greater activity over tranexamic acid in the models evaluated. In minipigs, a single subcutaneous dose achieved peak plasma levels within hours and sustained antifibrinolytic activity for approximately one week, supporting the potential for cycle-matched, once-per-cycle dosing. Such a dosing profile would represent a significant improvement over current short-acting therapies.

Heavy menstrual bleeding is “The Missed Vital Sign”. According to data compiled by Wellcome Leap’s international health initiative:

  • Reported in approximately 1 in 3 reproductive-aged women (American College of Obstetricians and Gynecologists)
  • 10 times more prevalent than asthma and diabetes in the same population
  • Leading cause of anemia and iron deficiency, which cause fatigue, shortness of breath and difficulty concentrating
  • Primary symptom driving a significant portion of the roughly 600,000 hysterectomies conducted in the U.S annually
  • 3.6 weeks of work missed annually per affected woman, costing the U.S. economy more than $94 billion
  • 11 academic weeks in total lost across the formative teenage years
  • Nearly 23 million women seeking care from a healthcare professional for heavy menstrual bleeding each year

“Millions of women and girls live with heavy menstrual bleeding and have no approved non-hormonal, long-acting treatment option,” said Benny Sørensen, MD, PhD, CEO of Hemab. “Dosing our first participant with HMB-003, purpose-built for the management of heavy menstrual bleeding, is the first step toward resetting the standard of care for these women. Beyond heavy menstrual bleeding, we believe HMB-003 has the potential to become a cornerstone therapy for underserved patients across several large indications. We look forward to sharing results that will inform our clinical development plans for heavy menstrual bleeding and provide insights into HMB-003’s potential for other bleeding conditions, no later than the middle of 2027.”

The Phase 1 study (NCT07798505) is a randomized, placebo-controlled, single-ascending-dose escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMB-003 in healthy adult volunteers. Results from this study are expected to inform dose selection and clinical development plans for HMB-003 across additional high-unmet-need bleeding conditions.

About Heavy Menstrual Bleeding
Heavy menstrual bleeding is a common condition characterized by excessive menstrual blood loss that disrupts a person’s physical, emotional, social, and daily life, affecting an estimated one in three reproductive-age women, or more than 23 million women in the U.S. alone. The condition is frequently associated with pain, iron-deficiency anemia, and fatigue, and carries a significant social burden, including stigma and substantial lost days from work and school. Current treatment options are limited. Tranexamic acid (TXA), the primary non-hormonal therapy, has a short half-life that requires frequent dosing throughout menstruation, limiting adherence. Hormonal therapies are not suitable, or not preferred, for many women. To date, there remains no approved non-hormonal, customized hemostatic treatment option for heavy menstrual bleeding.

About HMB-003
HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site, HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway. HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. For more information, please visit clinicaltrials.gov (NCT07798505).

About Hemab Therapeutics
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the clinical potential of HMB-003 for heavy menstrual bleeding and other indications and Hemab’s timeline for providing an update on its clinical development plans for HMB-003, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; whether Hemab’s cash resources will be sufficient to fund Hemab’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including Hemab’s most recent Form 10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:
Deerfield Group
Peg Rusconi
peg.rusconi@deerfieldgroup.com

Investors:
Hemab Therapeutics
Mads Behrndt
investors@hemab.com

References:
https://www.acog.org/womens-health/faqs/heavy-menstrual-bleeding
https://wellcomeleap.org/programs/the-missed-vital-sign/details/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8723888/
https://pmc.ncbi.nlm.nih.gov/articles/PMC3804006/

Cash redemption simplifies the capital structure with no common shares issued in the redemption

CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at their aggregate stated value of $6.0 million. Following the redemption, no shares of Series A Preferred Stock remain outstanding.

The redemption was funded with a portion of the net proceeds from the Company’s $15 million registered direct offering announced on September 9, 2026, consistent with the use of proceeds disclosed for that offering.

“We made a deliberate decision to redeem the Series A Preferred Stock in cash and eliminate the potential dilution these securities represented for our shareholders,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “Our recent financing enabled us to retire all outstanding Series A Preferred Stock before its discounted conversion feature became available, simplifying our capital structure without issuing common shares in the redemption. As we advance NEO100 and NEO212, disciplined management of shareholder capital remains central to our strategy. We are focused on translating clinical progress into lasting value for patients and shareholders.”

NeOnc issued the Series A Preferred Stock in June 2026 in a private placement for gross proceeds of $5.0 million. Under its terms, the Company had the right to redeem all outstanding shares for cash at stated value within four months of issuance. Had the Company elected not to redeem, the stated value would have increased by $166.67 per share, and the shares would have become convertible, at the holders’ option, into NeOnc common stock at a conversion price equal to 80% of the lowest closing price during the five trading days prior to conversion, subject to a $1.00 floor price.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the advancement of NEO100 and NEO212, the Company’s clinical development and capital management strategies, and its ability to translate clinical progress into long-term value for patients and shareholders. These statements are based on management’s current expectations and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially.

The Company undertakes no obligation to update any forward-looking statement except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com 

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com 
205-566-3026

This press release was published by a CLEAR® Verified individual.

ROUYN-NORANDA, Quebec, Sept. 17, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Company”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to announce a major update regarding the optimization of its capital structure. Following the massive conversion of its warrants expiring in September, the Company also confirms the execution of a highly stringent lock-up agreement binding its key executives for the benefit of Glencore AG.

Key Highlights:

  • Successful Warrant Conversions: Nearly all warrants expiring in September have been exercised, including 100% of those held by Company insiders. The remaining balance of warrants maturing in 2026 now stands at less than 21 million units. The exercise of these warrants added $3,290,485.00 to the treasury in 2026.
  • Immediate Removal of ~32% of Shares from the Public Float: Key executives have frozen 100% of their current controlling shares.
  • Dilution Protection: An automatic lock-up provision is in place for approximately 100 million additional convertible securities held by management in the event of future exercise.
  • Strengthened Support for Glencore Debt: This commitment aligns directly with the senior secured debt, which has been increased to US$40,000,000.

A Significant Strategic Alignment Commitment

Following the closing of the US$10,000,000 increase in debenture financing announced on September 2, 2026, Abcourt’s directors and senior management team are formalizing their long-term vision and confidence in the success of the flagship Sleeping Giant and Flordin projects.

Key Terms of the Lock-Up Agreement

The agreement executed by key executives (Noureddine Mokaddem, Pascal Hamelin, François Mestrallet, and Alain Lévesque) establishes institutional-grade retention terms while providing standard flexibility mechanisms:

  • Capital and Future Securities Freeze: Lock-up of approximately 32% of the outstanding share capital. Restrictions apply to all securities currently held or subsequently acquired (including shares resulting from the future exercise of options or warrants), whether held directly or indirectly by the executive or members of their immediate family.
  • Trading Restrictions (Subject to Consent): Unless prior written consent is obtained from Glencore (which shall not be unreasonably withheld), it is prohibited to sell, transfer, lend, pledge, assign, enter into short sales, or use any derivative, swap, or hedging strategy intended to transfer the economic risk associated with the securities.
  • Specific Permitted Exceptions: Lock-up restrictions do not apply to the following circumstances:
    • Death of the Executive: The legal transfer of securities to the estate and subsequent dispositions by the estate are fully authorized.
    • Family and Corporate Planning: Transfers to immediate family members, holding companies, or family trusts controlled by the executive are permitted, provided that the transferee signs an identical lock-up commitment.
    • Settlement of Tax Obligations: The sale of the minimum number of shares required to fund tax liabilities arising from the exercise of options or warrants is permitted within 30 days of the exercise, subject to providing detailed written notice to Glencore.
    • Change of Control (Takeover Bid): Securities may be tendered to a bona fide takeover bid or a merger targeting all shareholders (the lock-up is reinstated if the transaction is not completed).
  • Duration Linked to Debt Repayment: The lock-up remains in effect until the later of:
    • The 2nd anniversary of the amending agreement with Glencore;
    • 10 days after the full cash repayment of at least 75% of the US$40,000,000 debt principal (including interest). In the event of a financial default under the debenture, the lock-up is automatically extended.
  • Rigorous Control and Enforcement: Abcourt’s official transfer agent has received strict legal instructions to apply restrictive legends (stop-transfer orders) and to reject any unauthorized transactions.

Pascal Hamelin, President and Chief Executive Officer of Abcourt, stated:

“This lock-up agreement and the full exercise of our warrants demonstrate the absolute, long-term commitment of the entire management team to the success of the Sleeping Giant and Flordin projects. By freezing the securities of key individuals until the project’s ultimate success, we ensure maximum staff retention and motivation. For our shareholders, this provides a major guarantee of stability: by immediately locking up nearly one-third of our outstanding shares and all of our convertible securities until our financial partnership with Glencore is repaid, we strengthen our capital structure and 100% align our personal interests with value creation at Abcourt Mines.”

About Abcourt Mines Inc.

Abcourt Mines Inc. is a Canadian gold development company with properties strategically located in northwestern Quebec, Canada. Abcourt owns the Sleeping Giant mine and mill and the Flordin property, where it focuses its activities.

For further information about Abcourt Mines Inc., please visit our website at www.abcourt.ca and the documents filed under our profile on the SEDAR+ website at www.sedarplus.ca

Pascal Hamelin  Dany Cenac Robert
President and CEO  VP Communication and Corporate Development
T : (819) 768-2857 T : (514) 722-2276, poste 456
Email : phamelin@abcourt.com  Email : ir@abcourt.com
   

FORWARD-LOOKING STATEMENTS

Certain information contained in this press release may constitute “forward-looking information” within the meaning of Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “aims”, “expects”, “projects”, “intends”, “anticipates”, “estimates”, “could”, “should”, “likely”, or variations of such words and phrases, or statements specifying that certain acts, events, or results “could”, “should” occur, “will occur”, or “will be achieved”, or other similar expressions. Forward-looking statements are based on Abcourt’s estimates and are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, level of activity, performance, or achievements of Abcourt to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Forward-looking statements are subject to business and economic factors and uncertainties, as well as other factors that could cause actual results to differ materially from these forward-looking statements, including the relevant assumptions and risk factors set forth in Abcourt’s public documents available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Although Abcourt believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements. Unless required by applicable securities laws, Abcourt disclaims any intention or obligation to update or revise any of these forward-looking statements or information, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET. The event will feature PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women’s Hospital) and Paul Yu, MD, PhD (Massachusetts General Hospital), as well as BOS expert Steven Hays, MD (UCSF Health) to discuss the current treatment landscape and unmet need for PH-ILD and BOS as well as the role for LAM-001 as a potential new therapeutic option. To register, click here.

The event will provide an overview of LAM-001, the Company’s proprietary investigational once-daily inhaled DPI formulation of rapamycin (mTOR inhibitor), currently in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS). The KOLs will discuss mTOR inhibition as a potentially disease modifying mechanism of action across these conditions, focusing on its potential role in suppressing pulmonary smooth muscle hyperproliferation, limiting fibroblast driven vascular and interstitial remodeling, and modulating inflammatory signaling, along with the unique potential advantages of delivering therapy through an inhaled route. The KOLs will review current treatment options as well as the emerging treatment landscape for each condition. Data from the recently presented Phase 2a trial of LAM-001 in pulmonary hypertension will be reviewed as well as the design and objectives of the ongoing Phase 2 BOS and Phase 2b PH-ILD studies.

A live question and answer session will follow the formal presentations.

About Aaron B. Waxman, MD, PhD
Aaron B. Waxman, MD, PhD, is Director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. Dr. Waxman’s clinical practice and research programs center on pulmonary arterial hypertension (PAH), right heart failure, thromboembolic disease, and the broader spectrum of pulmonary vascular disease. Across local and national efforts, Dr. Waxman has served as Principal Investigator on more than 15 clinical trials in pulmonary hypertension. These include the Phase 2 SPECTRA trial of sotatercept, which helped establish activin signaling inhibition as a novel therapeutic pathway in PAH, and the INCREASE trial of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease—a study that defined a new treatment standard for a previously underserved patient population. He has authored more than 180 peer-reviewed publications, and his research has been supported by the National Institutes of Health, including the National Heart, Lung, and Blood Institute.

About Paul Yu, MD, PhD
Paul Yu, MD, PhD is Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, where he holds the Charles and Elizabeth Sanders Endowed Chair. A physician-scientist trained in immunology and cardiovascular medicine, Dr. Yu’s research focuses on bone morphogenetic protein and transforming growth factor-beta signaling in cardiovascular homeostasis, repair, and disease. His work spans pulmonary vascular disease, cardiovascular rheumatology, and rare disorders such as fibrodysplasia ossificans progressiva. Dr. Yu has translated several scientific discoveries into therapeutics, including contributions to sotatercept for pulmonary arterial hypertension and the clinical repositioning of saracatinib for fibrodysplasia ossificans progressiva. He has published over 120 peer-reviewed studies and has been elected to the American Society for Clinical Investigation.

About Steven Hays, MD
Steven Hays, MD, is Medical Director of the UCSF Advanced Lung Disease and Lung Transplant Program and Professor of Medicine at the University of California, San Francisco. Under his leadership, the program has grown to be one of the nation’s largest transplant centers while consistently achieving superior outcomes, receiving INTERLINK’s Chairman’s Award for Transplant Excellence for three consecutive years. Dr. Hays brings deep clinical expertise across the full spectrum of advanced lung disease, including cystic fibrosis, alpha-1 antitrypsin deficiency, interstitial lung disease, and emphysema. A dedicated clinical investigator, Dr. Hays has served as principal investigator on NIH-funded, industry-sponsored, and investigator-initiated trials. His research portfolio spans lung transplant immunology, chronic lung allograft dysfunction, infectious disease, and transplant digital health. He has authored more than 110 peer-reviewed publications and has been an invited speaker at the American Thoracic Society, the International Society of Heart and Lung Transplantation, and the American Society of Transplantation, among others. He is a Fellow of the American College of Chest Physicians, and a member of the American Thoracic Society and the International Society of Heart and Lung Transplantation, where he serves on the Pulmonary and Infectious Disease Councils. He is a recipient of the American Thoracic Society’s Outstanding Clinician Award (California Chapter) and a member of the prestigious UCSF Council of Master Clinicians.

About LAM-001

LAM-001 is a proprietary, investigational, once-daily inhaled formulation of rapamycin, also known as sirolimus. LAM-001’s potential as a disease-modifying agent in PH stems from its ability to inhibit mTOR-mediated pulmonary arterial smooth muscle cell proliferation, to limit endothelial cell dysfunction, and to suppress inflammatory signaling, leading to improvement in pulmonary vascular remodeling. The mTOR pathway has been shown to be activated in pulmonary arteries of patients with PH, and mTOR inhibition with rapamycin has been shown to reverse smooth muscle cell hyperproliferation and to attenuate pulmonary vascular remodeling and cardiopulmonary dysfunction in multiple published nonclinical models. Additionally, in published non-clinical studies, hyperactive mTOR signaling has been shown to promote fibroblast activation, myofibroblast differentiation, and extracellular matrix deposition in injured or inflamed lung tissue, and mTOR inhibition has been shown to exert direct antifibrotic activity, suppressing profibrotic cytokine signaling, reducing collagen accumulation, and attenuating parenchymal fibrosis. These effects are particularly relevant in PH-ILD, where vascular remodeling and progressive fibrosis evolve in parallel and amplify pulmonary vascular load. LAM-001 is designed to enhance pulmonary delivery and to reduce systemic exposure of rapamycin, offering a promising, potentially disease-modifying, therapy for multiple pulmonary diseases.

LAM-001 is currently being studied in multiple indications including PH-ILD, a serious and progressive condition affecting an estimated 200,000 patients between the U.S. and Europe. Based on compelling Phase 2a data presented at the American Thoracic Society (ATS) in May 2026, the company has advanced LAM-001 into a Phase 2b PH-ILD trial and data is anticipated in the first quarter of 2028. LAM-001 is also being evaluated in a Phase 2 study in bronchiolitis obliterans syndrome post lung transplant (BOS), a serious complication with an estimated prevalence of ~30K patients between the U.S. and Europe by 2032. The trial is fully enrolled, and data is anticipated in the first quarter of 2027. In late 2026, the company also plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of pulmonary sarcoidosis with no approved therapy, that affects an estimated ~60K patients in the U.S. and Europe.

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.

Forward-Looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” “designed,” “aims,” or other similar words. Examples of forward-looking statements include, among others, statements relating to the design and potential benefits of LAM-001, including as a disease-modifying therapy for pulmonary disease; anticipated regulatory and development processes and timelines, including the expected timing to initiate the planned Phase 2 trial of LAM-001 in SAPH, the expected timing for data readouts from the ongoing Phase 2 trial of LAM-001 in BOS and the ongoing Phase 2b trial of LAM-001 in PH-ILD; the Phase 2a data of LAM-001 in PAH and PH-ILD supporting continued development of LAM-001 in PH-ILD and the potential benefit across exercise capacity, pulmonary hemodynamics, cardiac stress and lung function; observed improvements in 6MWD and PVR in the Phase 2a trial potentially suggesting broader effects on cardiopulmonary physiology; the estimated patient populations in the U.S. and Europe for PH-ILD, BOS and SAPH; and the potential advantages of mTOR inhibitors in PH-ILD, BOS and SAPH. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to LAM-001; the ability to obtain and maintain regulatory approval; competition in the company’s industry; the scope, progress and expansion of developing LAM-001; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; the company’s ability to attract or retain key management, members of the board of directors and other personnel; the company’s ability to fund its operations and clinical development plans, including its anticipated cash runway; the impacts of general macroeconomic and geopolitical conditions on the company’s business and financial position; and other risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on August 14, 2026 and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.

Contacts

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK® (also known as AB-101), in refractory rheumatoid arthritis (RA) in the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity for a range of antibodies, including anti-CD20 antibodies, and drive deep B-cell depletion. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases, together with a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK to drive deep B-cell depletion through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness and safety of AlloNK; Artiva’s Phase 3 registrational trial for AlloNK®; and Artiva’s participation in the Stifel 2026 Virtual Immunology and Inflammation Forum. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks inherent in developing product candidates and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Artiva Biotherapeutics, Inc.

CONTACT: Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

LockeT Has Expanded to Six Hospitals in Brazil Since Its August Launch

Company Engages Experienced Cardiology Group to Support Expansion Across Argentina, Chile, Colombia and Additional Latin American Markets

FORT MILL, S.C., Sept. 17, 2026 (GLOBE NEWSWIRE) —  Catheter Precision Inc. (NYSE American: VTAK), Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company specializing in cardiac electrophysiology, today announced the expansion of its LockeT commercialization efforts across Latin America following the product’s successful introduction in Brazil.

LockeT launched commercially in São Paulo in August through the Company’s distribution agreement with Ablacor and has since expanded to six hospitals in Brazil, with additional interest from healthcare institutions in the market.

Building on the initial traction in Brazil, Catheter Precision has expanded its relationship with an experienced cardiology group with extensive clinical knowledge and longstanding relationships throughout Latin America to support the Company’s continued commercial expansion across the region.

The Company is now pursuing opportunities to expand LockeT into additional Latin American markets, including Argentina, Chile and Colombia, as well as other countries throughout the region.

“The early response to LockeT in Brazil has been very encouraging and has given us confidence to broaden our efforts across Latin America,” said David Jenkins, Chief Executive Officer of Catheter Precision. “Expanding to six hospitals in a relatively short period demonstrates the potential we see for LockeT internationally. We believe the clinical experience and established relationships of the cardiology group we are working with can be valuable as we introduce LockeT into additional markets throughout the region.”

Building on Early Commercial Traction in Brazil

Catheter Precision entered the Brazilian market through a distribution agreement with Ablacor, initially launching LockeT in São Paulo in August 2026.

Since that introduction, LockeT has expanded to six hospitals, providing the Company with an initial commercial foundation in one of Latin America’s largest healthcare markets.

The Company believes the early progress in Brazil provides a model for expanding LockeT’s international commercial presence across additional markets where electrophysiology procedures are performed.

Catheter Precision is now working with an experienced cardiology group with expertise in electrophysiology and established relationships throughout the region to support the next phase of that expansion.

The Company intends to build upon its presence in Brazil while pursuing commercial opportunities across Argentina, Chile, Colombia and additional markets throughout Latin America.

“Latin America represents an important opportunity for LockeT,” Jenkins continued. “Our focus is on building the market thoughtfully, working alongside experienced clinical groups and establishing strong relationships within each country we enter. Brazil was an important first step, and we are excited to continue expanding LockeT’s presence across the region.”

The expansion of LockeT in Latin America is part of Catheter Precision’s broader strategy to increase the international commercial reach of its cardiac electrophysiology product portfolio and establish relationships with physicians, hospitals and healthcare organizations in new markets.

About LockeT

Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.